News Sentiment

ALA sentiment intelligence

Arovella Therapeutics Limited news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 52 Balanced news tone 7 relevant articles
Exchange ASX Australia
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 0.07 Week of 10 Jul 2026
Weighted tone 52/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

78/100 classification confidence.

Company focus 7

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

-4.3% over one week, -1.5% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

Arovella secures FDA clearance to begin first-in-human trials of ALA-101 cell therapy

Market Reaction

Price moving ahead of tone

60/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 78/100 classification
One-week reaction -4.3% Price reacting lower
Trend fit Trend inactive -1.5% over four weeks
Fair value -40.8% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 1
Neutral 6
Negative 0

Relevance

Why the article matched

Direct first
Direct company coverage 7
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
Market source 2
BiotechDispatch 1
Kalkine Media 1
Market Index 1
TradingView 1
intelligentinvestor.com.au 1

Event Lens

What the news is about

Classified themes
Market update 5
Balance sheet 2

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-7 of 7